Katz Group names new COO
TORONTO — Retail pharmacy network Katz Group Canada has appointed Frank Scorpiniti as COO.
With more than 20 years of retail pharmacy experience, Scorpiniti previously was SVP pharmacy operations at Duane Reade. Prior to Duane Reade, he held positions of increasing responsibility at Longs Drug Stores.
“Frank is a strategic thinker who has a passion for the retail pharmacy industry, and a proven ability to drive growth and performance within an organization,” stated Andy Giancamilli, CEO of Katz Group Canada. “We are confident that Frank’s leadership and experience will help enhance the customer experience across our network of corporate, franchise and banner pharmacies.”
The company also announced the appointment of Warren Jeffery as chief development officer, which Jeffery will assume in addition to his current role as interim chief merchandising officer. Reporting to Giancamilli, Jeffery will lead the company’s productivity and growth initiatives.
Katz Group Canada’s retail pharmacy network encompasses more than 1,800 chain, franchise and independent pharmacies across the country. Pharmacy banners include Rexall, Rexall Pharma Plus, The Medicine Shoppe, Guardian and I.D.A. Katz Group’s holdings also include Rexall Specialty Pharmacy, Rexall Direct, Rexall Health Services and ProPharm Limited.
Cephalon files bid document for ChemGenex
FRAZER, Pa. — Cephalon has lodged a bidder’s statement to acquire Australian drug maker ChemGenex Pharmaceuticals for $167 million, Cephalon said Wednesday.
Cephalon, which said its offer of 70 Australian cents per share represented a premium of nearly 60% over ChemGenex’s stock price as of March 29, said the Australian company’s directors had unanimously recommended approval of the acquisition. ChemGenex specializes in developing treatments for cancer.
“The addition of ChemGenex’s compounds supports our commitment to building a world-class pipeline that delivers first-in-class therapies to patients suffering from serious, often life-threatening medical conditions,” Cephalon CEO Kevin Buchi said.
Diabetes stakeholders discuss how healthcare-reform law affects patients
NEW YORK — Healthcare reform has remained a major subject of debate since President Barack Obama signed the Patient Protection and Affordable Care Act last March, but what the law means for diabetes care was the particular focus of a conference call with diabetes stakeholders Tuesday.
The conference call, sponsored by healthcare research firm Avalere Health, discussed various provisions in the healthcare-reform law that affect patients with diabetes, including incentives for prevention of chronic disease in Medicaid, the creation of the National Diabetes Prevention Program, coverage expansion and elimination of co-payments for preventive services and immunizations.
“It’ll be interesting to see what the results of some of these initiatives are and how they affect care,” Avalere manager Kathleen Gravelle said.
Much of the discussion focused on the role of the physician, but Novo Nordisk senior director of government affairs Christopher Porter also emphasized the role of pharmacists.
“Obviously, there’s a number of places that communities and initiatives have involved pharmacists, and there have been tremendous results,” Porter said. “From our perspective, we see the pharmacist as really a key person.”
Indeed, pharmacists’ accessibility and ability to work directly with patients could be a particular asset, especially as the incidence and costs of diabetes are set to dramatically rise in the coming years. According to the Centers for Disease Control and Prevention, 25.8 million Americans have diabetes, and the cost of treating the disease, $299 billion in 2010, is expected to rise to $374 billion by 2015 and to $514 billion in 2025.